Benjamin Tsai
Consultant @ TMG Capital
New York, United States
Benjamin Tsai is a Series B investor at TMG Capital in New York focused on FinTech and Financial Services. Partner at Invus Opportunities, a sister fund to The Invus Group, an equity investment firm founded in 1985 with over $8 billion of evergreen capital. Invus Opportunities is focused on partnering with market-leading management teams and investors in private transactions globally. With a differentiated heritage and capital base, Invus Opportunitiesbrings a complementary dimension to growing companies and investor groups seeking to create lasting value. Invus Opportunities both leads rounds of financing and co-invests in syndicated financings, and currently manages over $1.5 billion.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 71%
Last updated:
For AI agents: llms.txt
Industries Benjamin Tsai invests in
Stages Benjamin Tsai invests in
Countries Benjamin Tsai invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- FinTech 3 (43%)
- Financial Services 3 (43%)
- Credit 2 (29%)
- Medical 2 (29%)
- Mobile 1 (14%)
Stage
- Series B 2 (29%)
- Series C 2 (29%)
- Funding Round 1 (14%)
- Private Equity 1 (14%)
- Secondary Market 1 (14%)
Country
- United States 4 (57%)
- United Kingdom 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
PayJoy
|
PayJoy is a mission-first credit provider dedicated to helping under-served customers in emerging markets to achieve financial stability and success. Our patented technology for secured credit provides an on-ramp for new customers to enter the credit system. Through PayJoy’s point-of-sale financing and card offerings, customers gain access to amodern quality of life. PayJoy’s credit also allows our customers to seize opportunities as micro-entrepreneurs, and acts as insurance for tough times. Through our cutting-edge machine learning, data science, and anti-fraud AI, we have served nearly 20 million customers and lent nearly $4B as of 2026 while achieving solid profitability and growth. | $150M / Series C / Sep 05, 2023 | |
Presidio Medical
|
Presidio Medical is a medtech company that develops a transformational neuromodulation platform. It enables people to receive remedies for disorders affecting neuronal activity. | $72M / Series C / Jun 26, 2023 | |
ClearScore
|
ClearScore is a financial technology company that provides credit scoring services and a marketplace. It provides access to financial data, including credit reports and scores, and open banking data. The company's business is dedicated to helping its users improve their financial well-being. | $200M / Private Equity / Jun 25, 2021 | |
|
ClearScore
|
ClearScore is a financial technology company that provides credit scoring services and a marketplace. It provides access to financial data, including credit reports and scores, and open banking data. The company's business is dedicated to helping its users improve their financial well-being. | Secondary Market / Jun 25, 2021 | |
|
Presidio Medical
|
Presidio Medical is a medtech company that develops a transformational neuromodulation platform. It enables people to receive remedies for disorders affecting neuronal activity. | $30M / Series B / Jul 14, 2020 | |
Oyster Point Pharmaceuticals
|
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as anasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU). | $93M / Series B / Feb 26, 2019 | |
Marlette Funding
|
Marlette Funding is a financial services technology company that is simplifying how consumers borrow money. Its team of consumer finance leaders developed and power the Best Egg personal loan product which can be used to consolidate debt and to finance purchases or services like home improvement or medical expenses. Through its streamlined onlineloan platform, qualified applicants can instantly review loan offers, select a loan and receive funds in as little as one day. |
Co-Investors
About TMG Capital
TMG Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Benjamin Tsai
Consultant
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Benjamin Tsai invest in?
Benjamin Tsai invests primarily in FinTech, Financial Services and Credit startups, most often at Series B and Series C stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Benjamin Tsai?
Public channels for Benjamin Tsai include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Benjamin Tsai last invest?
The most recent investment recorded for Benjamin Tsai closed in Sep 2023. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
